# Pizarra — PT-pseudo_20ba3f0f6ca0 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20ba3f0f6ca0
Task: 1

Encounter: Urology - outpatient on 01 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.086 ng/mL²
  - PSA velocity: 0.35 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7257912 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.

Vitals: weight 76 kg, height 188 cm, BMI 21.5, BP 131/58 mmHg, HR 71 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2023).

Chief complaint: A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation.

History: A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment.

Physical examination: DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: musician (semi-retired); Married; Recently relocated; lives with sister.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Walking 45 min/day; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.70 +/- 0.12   (95% CI 0.48-0.93)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.12  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.88 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant immediate action?
  - previous_notes (get_previous_notes) -> What is the established management context and prior surveillance pathway?

This case hinges on the interpretation of the mpMRI findings and the context provided by the PSA trend and prior management plan to confirm the guideline recommendation.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, which includes PSA 4.8 ng/mL, PI-RADS 4, and csPCa probability 0.7257912. It cannot account for the context provided by the mpMRI prose, the PSA velocity (0.35 ng/mL/yr), or the specific management context from the previous notes. It also ignores the DRE finding of a "Nodus" and the patient's low IPSS score (0/35).

WHY THE SUGGESTION COULD BE WRONG
The prior suggests biopsy based on a high probability (0.70), but the epistemic error (dp = 0.12) indicates significant uncertainty. This uncertainty means the suggestion could be highly sensitive to the specific training sample. Furthermore, the guideline criterion is based on PI-RADS 3 or higher, but the prior did not explicitly weigh the PSA density (0.086 ng/mL²) or the PSA velocity (0.35 ng/mL/yr), which are crucial for risk stratification according to the guideline search.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant immediate action?
previous_notes - What is the established management context and prior surveillance pathway?
laboratory panel - What are the full laboratory results, specifically to confirm PSA density and rule out other factors?

GUIDELINE ANCHOR
The guideline states that MRI-directed biopsy is the standard of care when MRI shows a suspicious lesion (PI-RADS $\ge 4$), and it provides specific criteria for omitting biopsy when MRI is negative (PI-RADS $\le 2$) and clinical suspicion is low.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Study: Multiparametric MRI Prostate | Facility: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch) | Date: 28 Dec 2024
The report identifies a PI-RADS 4 lesion in the right peripheral zone mid-gland, measuring 12 x 9 x 8 mm, with restricted diffusion and early focal enhancement. It notes a prostate volume of 56.0 mL and a PSA density of 0.086 ng/mL/mL, with a csPCa predicted probability of 0.7257912.

get_psa_trend
The PSA trend shows a trajectory: 4.1 ng/mL (May 2023) -> 4.5 ng/mL (Oct 2023) -> 4.5 ng/mL (Mar 2024) -> 2.9 ng/mL (Aug 2024) -> 4.8 ng/mL (Jan 2025). The trend is not strictly rising, showing fluctuation but ending at 4.8 ng/mL.

get_previous_notes
The previous notes document a consultation on 06 May 2024 where a PSA of 3.6 ng/mL was noted, with a slow upward trajectory. A urology consultation and mpMRI were coordinated. The notes confirm no prior biopsy and no established treatment plan.

NOT RETRIEVED
laboratory panel
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no specific question arose from the retrieved documents that necessitated its opening.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right peripheral zone mid-gland.
- PSA trend: The PSA has fluctuated but is currently at 4.8 ng/mL, following a period of fluctuation.
- Previous notes: The patient was referred for mpMRI due to a progressive PSA increase, establishing a context for further investigation.

AGAINST sampling this patient now:
- PSA trend: The PSA trend is not strictly rising, showing fluctuation.

WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the PI-RADS 4 finding on the MRI, aligning with the guideline criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 4 finding from the MRI report, strongly supports the guideline criterion for biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across the prior, protocol, and evidence. The PI-RADS 4 finding on the mpMRI report was decisive, aligning with the guideline criterion for biopsy when PI-RADS is 3 or higher. This finding was the key retrieved piece of evidence that confirmed the recommendation, overriding any potential uncertainty from the statistical prior.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
